Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL1614072 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL756143 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Hexane SCHEMBL19611429 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL31373773 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL11889416 | 0.98 | DGKA (0.62) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL27394742 | 0.98 | DGKA (0.61) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL3483756 | 0.93 | DGKA (0.56) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL4168022 | 0.93 | DGKA (0.56) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL3310609 | 0.93 | DGKA (0.56) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Acetone SCHEMBL1868300 | 0.92 | DGKA (0.69) | DGKAPAMLMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-0214743-B1 | USE OF QUINOLINE DERIVATIVES IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF CEREBROVASCULAR DISORDERS AND CEREBRAL SENILITY | BEECHAM GROUP PLC (GB) | 1993-05-12 | — | — | EP | disclosed |
| US-4808619-A | HYPOTENSIVE AGENT, COGNITION ACTIVATOR | BEECHAM GROUP P.L.C. (GB) | 1989-02-28 | — | — | US | disclosed |
| EP-0214743-A2 | Use of quinoline derivatives in the manufacture of medicaments for the treatment of cerebrovascular disorders and cerebral senility | BEECHAM GROUP PLC (GB) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | DGKA 3071/4885PAM 393/4885LMNA 4134/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | DGKA 3608/4885PAM 385/4885LMNA 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.